Pharming Historical Financial Ratios
| PHAR Stock | USD 9.27 0.53 6.06% |
Pharming Group is promptly reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.25, Invested Capital of 0.0, Average Payables of 6.4 M or Stock Based Compensation To Revenue of 0.0358 will help investors to properly organize and evaluate Pharming Group NV financial condition quickly.
Pharming |
About Pharming Financial Ratios Analysis
Pharming Group NVFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Pharming Group investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Pharming financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Pharming Group history.
Pharming Group Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Pharming Group NV stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pharming Group sales, a figure that is much harder to manipulate than other Pharming Group NV multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Research And Ddevelopement To Revenue
The ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services.Most ratios from Pharming Group's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Pharming Group's Payables Turnover is relatively stable compared to the past year. As of 12/12/2024, Days Payables Outstanding is likely to grow to 328.77, while PTB Ratio is likely to drop 3.92.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 3.93 | 2.89 | 1.74 | 1.78 | Days Of Inventory On Hand | 493.38 | 879.68 | 821.73 | 780.64 |
Pharming Group fundamentals Correlations
Click cells to compare fundamentals
Pharming Group Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pharming Group fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 6.97 | 4.75 | 3.58 | 4.99 | 3.81 | 3.62 | |
| Ptb Ratio | 11.25 | 5.91 | 3.52 | 5.01 | 4.27 | 3.92 | |
| Days Sales Outstanding | 50.66 | 30.76 | 30.53 | 34.75 | 63.41 | 60.24 | |
| Book Value Per Share | 0.0865 | 0.14 | 0.22 | 0.23 | 0.27 | 0.25 | |
| Free Cash Flow Yield | 0.0372 | 0.0686 | 0.0297 | 0.0204 | (0.0201) | (0.0211) | |
| Operating Cash Flow Per Share | 0.0886 | 0.11 | 0.0412 | 0.0259 | (0.0211) | (0.0221) | |
| Average Payables | 9.5M | 21.9M | 9.3M | 5.6M | 10.3M | 6.4M | |
| Capex To Depreciation | 4.39 | 1.84 | 0.85 | 0.15 | 0.0919 | 0.0873 | |
| Pb Ratio | 11.25 | 5.91 | 3.52 | 5.01 | 4.27 | 3.92 | |
| Ev To Sales | 6.88 | 4.56 | 3.42 | 4.79 | 4.25 | 4.04 | |
| Free Cash Flow Per Share | 0.0583 | 0.0873 | 0.023 | 0.0237 | (0.0228) | (0.024) | |
| Roic | 0.32 | 0.23 | 0.0613 | 0.0505 | (0.012) | (0.0114) | |
| Inventory Turnover | 1.48 | 1.2 | 0.74 | 0.41 | 0.44 | 0.42 | |
| Net Income Per Share | 0.0482 | 0.0442 | 0.0183 | 0.0155 | (0.0128) | (0.0135) | |
| Days Of Inventory On Hand | 247.27 | 305.26 | 493.38 | 879.68 | 821.73 | 780.64 | |
| Payables Turnover | 0.66 | 1.88 | 3.93 | 2.89 | 1.74 | 1.78 | |
| Sales General And Administrative To Revenue | 0.0904 | 0.11 | 0.0631 | 0.19 | 0.22 | 0.31 | |
| Research And Ddevelopement To Revenue | 0.17 | 0.18 | 0.35 | 0.26 | 0.28 | 0.27 | |
| Capex To Revenue | 0.13 | 0.0721 | 0.0841 | 0.009615 | 0.005968 | 0.005669 | |
| Cash Per Share | 0.0874 | 0.24 | 0.22 | 0.23 | 0.26 | 0.25 | |
| Pocfratio | 17.7 | 11.93 | 18.8 | 44.77 | (53.96) | (51.26) | |
| Interest Coverage | 5.11 | 12.83 | 4.71 | 3.4 | (0.82) | (0.86) | |
| Capex To Operating Cash Flow | 0.34 | 0.18 | 0.44 | 0.0863 | (0.0846) | (0.0804) | |
| Pfcf Ratio | 26.87 | 14.57 | 33.68 | 49.01 | (49.75) | (47.26) | |
| Days Payables Outstanding | 552.59 | 194.05 | 92.91 | 126.27 | 210.1 | 328.77 | |
| Income Quality | 1.09 | 1.92 | 1.64 | 1.53 | 1.44 | 0.9 | |
| Roe | 0.35 | 0.21 | 0.083 | 0.0668 | (0.0482) | (0.0506) | |
| Ev To Operating Cash Flow | 17.48 | 11.46 | 17.97 | 43.0 | (60.31) | (57.29) | |
| Pe Ratio | 32.55 | 28.76 | 42.46 | 74.97 | (88.51) | (84.09) | |
| Return On Tangible Assets | 0.23 | 0.12 | 0.0511 | 0.039 | (0.0269) | (0.0283) | |
| Ev To Free Cash Flow | 26.54 | 13.99 | 32.18 | 47.06 | (55.6) | (52.82) | |
| Earnings Yield | 0.0307 | 0.0348 | 0.0235 | 0.0133 | (0.0113) | (0.0119) | |
| Intangibles To Total Assets | 0.24 | 0.31 | 0.22 | 0.21 | 0.18 | 0.15 | |
| Net Debt To E B I T D A | (0.23) | (0.47) | (0.62) | (1.21) | 11.12 | 11.67 | |
| Current Ratio | 1.05 | 3.43 | 5.33 | 4.65 | 4.06 | 2.24 | |
| Tangible Book Value Per Share | 0.0451 | 0.1 | 0.12 | 0.15 | 0.18 | 0.28 | |
| Receivables Turnover | 7.21 | 11.87 | 11.95 | 10.5 | 5.76 | 9.97 | |
| Graham Number | 0.35 | 0.26 | 0.39 | 0.46 | 0.3 | 0.28 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.